Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mainz Biomed (MYNZ) Total Current Liabilities (2020 - 2025)

Mainz Biomed's Total Current Liabilities history spans 5 years, with the latest figure at $5.9 million for Q4 2024.

  • For Q4 2024, Total Current Liabilities fell 35.59% year-over-year to $5.9 million; the TTM value through Dec 2024 reached $5.9 million, down 35.59%, while the annual FY2024 figure was $5.9 million, 35.59% down from the prior year.
  • Total Current Liabilities for Q4 2024 was $5.9 million at Mainz Biomed, down from $9.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $9.2 million in Q4 2023 and bottomed at $701954.0 in Q4 2020.
  • The 5-year median for Total Current Liabilities is $4.2 million (2022), against an average of $4.3 million.
  • The largest annual shift saw Total Current Liabilities soared 213.86% in 2022 before it tumbled 35.59% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $701954.0 in 2020, then soared by 92.57% to $1.4 million in 2021, then skyrocketed by 213.86% to $4.2 million in 2022, then soared by 117.72% to $9.2 million in 2023, then crashed by 35.59% to $5.9 million in 2024.
  • Per Business Quant, the three most recent readings for MYNZ's Total Current Liabilities are $5.9 million (Q4 2024), $9.2 million (Q4 2023), and $4.2 million (Q4 2022).